MedTrace Logo

Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)

NCT07767253 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2026-08-17

No results posted yet for this study

Summary

This study is a 2-part (parts A and B) study.The primary objective of the study is to evaluate the efficacy of 611 in Chinese Children with moderate to severe atopic dermatitis (AD).

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

611

Solution for injection, subcutaneous (SC)

DRUG

611

Solution for injection, subcutaneous (SC)

DRUG

Matching placebo

Solution for injection, subcutaneous (SC)

Sponsors & Collaborators

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Lin Ma, Doctor · Beijing Children's Hospital

  • ZiGang Xu, Doctor · Beijing Children's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2027-09-30
Completion
2028-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07767253 on ClinicalTrials.gov